Hopstem Presents Positive 18-Month Phase I Clinical Data of hNPC01 for Ischemic Stroke at ISSCR 2025
Hopstem Biotechnology
iPSC Cell Therapy Product Developer
Bayer
Pharmaceutical Product R&D Developer
BlueRock Therapeutics
Induced Pluripotent Stem Cell (iPSC) Therapy Developer
Boston, Massachusetts, USA —— December 11, 2025——Hopstem Biotechnology Invited to2025 International Society for Stem Cell Research (ISSCR) International Symposium on Pluripotent Stem Cell-Derived TherapiesCompany Announces Its Self-Developed iPSC-Derived Cell Therapy ProducthNPC01Injection Solution18-Month Follow-Up Data from Phase 1 Clinical Trial. This year's conference focuses on the development and commercialization of pluripotent stem cell-derived products entering the clinical stage, bringing together top global forces and the latest clinical breakthroughs in this field.
During the conference, leading international companies in pluripotent stem cells, such asBayer/BlueRock Therapeutics、Vertex Pharmaceuticals、Neurona Therapeutics、Astellaset al. also announced significant clinical progress in their PSC-derived cell therapy programs, covering multiple therapeutic areas such as neurological, metabolic, and neurodegenerative diseases. Meanwhile, several internationally renowned scientists, includingProfessor Hideyuki Okano, Professor Takehiko Kaneko, Dr. Jane LebkowskiThey also shared the latest clinical results in myocardium, spinal cord injury, and ophthalmology directions, and conducted in-depth discussions on key issues such as clinical safety and efficacy evaluation, commercialization preparation, GMP-grade pluripotent stem cell lines, large-scale production capabilities, and later-stage clinical development pathways.
Agenda of the Conference
Dr. Fan Jing, founder and CEO of Hopstem Biotechnology, was invited to give a special report. The excellent efficacy data of hNPC01 in the Phase I clinical study conducted in China has attracted high attention from researchers and industry peers, marking that China's high-quality clinical research on pluripotent stem cells is also at the forefront internationally.
"The scientific research and clinical achievements showcased at this year's symposium demonstrate that multiple pluripotent stem cell-derived therapies are entering the next critical stage of development," said Dr. Fan Jing. "We are honored to share the clinical data of hNPC01 on this global platform. As a leading product in the market with scarce availability, these forebrain neural precursor cells have already shown significant potential in treating long-term motor dysfunction after stroke in Phase I clinical trials. Hopstem Biotechnology will continue to advance the global clinical development of hNPC01, bringing safe, effective, accessible, and groundbreaking regenerative medicine therapies to patients with unmet clinical needs such as stroke and traumatic brain injury."”
Hopstem Biotechnology Inc.2017Year1Founded in [Month], it is a globally innovative company focused on development.iPSCA biotechnology company developing universal cell therapy products, with a total of6400Square Cell Drug Research and Development Center,GMPCell production workshop, quality control center, and office space. Hopstem Biotechnology iniPSCHas leading global patents and innovative technological advantages in reprogramming, neural differentiation of pluripotent stem cells, and various cell engineering fields, establishingiPSCCell ProductsCMCPlatform, fully suspended automatic production process and various innovative analysis methods. Hopstem Biotechnology has established a platform for commercial licensing both in and outside of China.GMP iPSCCell lines, and has multiple products under development (including various neural cells, ophthalmic cells, etc.), among which the first human prefrontal cortex neural progenitor cells hNPC01 Injection Solutions in China and the United States IND The application is the earliest approved in China, has completed Phase I clinical trials, and obtained FDA Fast Track Designation, currently the fastest developing in its class internationallyiPSCCellular products can address significant unmet clinical needs such as stroke, sequelae of traumatic brain injury, cerebral palsy, and epilepsy.
Relevant Links:
Combining Pluripotent Stem Cells and Directed Differentiation Technology
Better Understand and Treat Human Diseases